Association between chemotherapy-related cardiac dysfunction (CTRCD) and 6-minute walking distance (6MWD) in breast cancer patient receiving anthracycline-based chemotherapy
Abstract
Anthracycline chemotherapy is one of the most commonly given therapies to breast cancer patients. Anthracycline has a cardiotoxicity effect causing cardiac myocyte death. This chemotherapy-related cardiac dysfunction (CTRCD) will decrease oxygen delivery to tissues characterized by reduced cardiorespiratory fitness. The 6-min walking distance (6MWD) could be a predictor of cardiorespiratory fitness. This study aimed to investigate the association between CTRCD and the reduction in 6MWD after receiving anthracycline-based chemotherapy. It was an analytical observational study with a retrospective cohort design that conducted on breast cancer patients underwent anthracycline-based chemotherapy. Subjects were patients from the Cardio-oncocare registry who met the inclusion and exclusion criteria. The CTRCD was assessed using left ventricle ejection fraction (LVEF) and global longitudinal strain (LVGLS) by transthoracic echocardiography examination based on criteria from the European Society of Cardiology guidelines. The 6MWD was assessed by performing 6-min walking tests. The LVEF, LVGLS and 6MWD data were retrieved from the Cardio-oncocare registry database, which were performed before and after chemotherapy. The changes and association of LVEF, LVGLS and 6MWD from before to end of chemotherapy were analyzed. Of 250 Cardio-oncocare registered patients, 58 patients met the criteria. Among them, 17 patients (29%) had CTRCD, and 41 patients (71%) had no CTRCD after chemotherapy. A significant decrease in LVEF and LVGLS in patients with CTRCD was observed. The 6MWD before chemotherapy did not statistically differ between CTRCD and no CTRCD patients. After chemotherapy, the proportion of patients experienced reduction of 6MWD was not significantly different between CTRCD patients and no CTRCD patients [7 patients (41%) vs. 21 patients (51%); p=0.342]. In conclusion, there is no significant association between CTRCD and reduction of 6MWD in breast cancer patients receiving antracycline-based chemotherapy.
References
Angahar LT. An overview of breast cancer epidemiology, risk factors, pathophysiology, and cancer risks reduction. MOJ Biol Med, 2017;1(4):92‒6.
http://dx.doi.org/10.15406/mojbm.2017.01.00019
Gautama, W. Breast cancer in Indonesia in 2022: 30 years of marching in place. Indones J Cancer, 2022;16: 1.
http://dx.doi.org/10.33371/ijoc.v16i1.920
The Global Cancer Observatory (Globocan) Indonesia. Geneva: World Health Organization; 2020.
Jogja Cancer Registry. Laporan Registrasi Kanker Berbasis Rumah Sakit periode Maret 2022 [Internet]. Jogja; 2022. Available from: RKBR Maret 2022 – canreg.fk.ugm.ac.id
Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy–related cardiac dysfunction and heart failure. Circ Heart Fail 9, 2015: e002661.
https://doi.org/10.1161/CIRCHEARTFAILURE.115.002661
Lyon AR, Dent S, Stanway S, Earl H, Brezden‐Masley C, Cohen‐Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society. Eur J Heart Fail, 2020; 22: 1945–60.
https://doi.org/10.1093/eurheartj/ehac244
Chakkera HA, Angadi SS, Heilman RL, Kaplan B, Scott RL, Bollempalli H, et al. Cardiorespiratory fitness (peak oxygen uptake): safe and effective measure for cardiovascular screening before kidney transplant. J Am Heart Assoc, 2018;7: e008662.
http://doi.org/10.1161/JAHA.118.008662
Bonsignore A, Marwick TH, Adams SC, Thampinathan B, Somerset E, Amir E, et al. Clinical, echocardiographic, and biomarker associations with impaired cardiorespiratory fitness early after HER2-targeted breast cancer therapy. JACC Cardio Oncol, 2021;3: 678–91.
https://doi.org/10.1016/j.jaccao.2021.08.010
Guazzi M, Dickstein K, Vicenzi M, Arena R. Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail, 2009;2: 549–55.
https://doi.org/10.1161/CIRCHEARTFAILURE.109.881326.
But-Hadzic J, Dervisevic M, Karpljuk D, Videmsek M, Dervisevic E, Paravlic A, et al. Six-minute walk distance in breast cancer survivors—a systematic review with meta-analysis. Int J Environ Res Public Health, 2021;18: 2591.
https://doi.org/10.3390/ijerph18052591
Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, et al. The congenital heart disease in adult and pulmonary hypertension (COHARD-PH) registry: a descriptive study from single center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord, 2020;20: 1-11
https://doi.org/10.1186/s12872-020-01434-z
Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol, 2019; 13: 117954681986644.
https://doi.org/10.1177/1179546819866
Muckiene G, Vaitiekus D, Zaliaduonyte D, Zabiela V, Verseckaite-Costa R, Vaiciuliene D, et al. Prognostic impact of global longitudinal strain and NT-proBNP on early development of cardiotoxicity in breast cancer patients treated with anthracycline-based chemotherapy. Medicina (Mex.), 2023;59: 953.
https://doi.org/10.3390/medicina59050953
Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med, 2020;7: 26.
http://doi.org/10.3389/fcvm.2020.00026
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2015;28: 1-39.e14.
http://dx.doi.org/10.1016/j.echo.2014.10.003
Bayram E, Gulcu O, Aksu U, Aksakal E, Birdal O, Kalkan K. Evaluating the association between the three different ejection fraction measurement techniques and left ventricle global strain. Eurasian J Med, 2018; 50(3):173-7.
https://doi.org/10.5152/eurasianjmed.2018.17409
Sinclair RC, Batterham AM, Davies S, Cawthorn L, Danjoux GR. Validity of the 6 min walk test in prediction of the anaerobic threshold before major non-cardiac surgery. Br J Anaesth, 2012;108(1):30-5.
